Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 1997

View Archived Issues

New alpha1-adrenoceptor antagonist evaluated

Medtronic and Somnus to codevelop snoring and sleep apnea therapy

Allelix adds two neuropharmaceutical development programs in Q2 1997

Allergan: Q1 1997 highlights

Genentech: Q1 1997 highlights

Warner-Lambert reaffirms goal of average EPS growth in mid-teens for balance of century

Neurotrophic/neuroprotective agents described by Synthelabo

Allergan claims prostaglandin derivatives with vasodilating activity

Substance P and bradykinin antagonists from Kyowa Hakko

MiniMed and Trimeris collaborate to deliver HIV therapy

Roussel Uclaf claims new cephalosporins

NovaDx discovers osteoporosis drug opportunities

Biosource awarded grant for human therapeutic protein production

Antitumor agents described by Sagami

PRIZM announces gene targeting results

BTG licenses Campath-1H to LeukoSite

Shareholder meeting set for Vaxel/Zynaxis merger

Antiarthritic activity and mechanism of action of mercaptoethylguanidine

CoCensys discovers potent, water-soluble allosteric modulators of GABA-A receptor

Titan issued U.S. patent for cancer vaccine

Lilly prepares water-soluble echinocandin antifungal agents

Mylan Laboratories's Acyclovir receives FDA approval

Novel marine antioxidant described by UNC researchers

Bioniche reports positive clinical results for Regressin

Amino-ketones from Roche found to lower cholesterol levels in animals

Mimetix initiates clinical trial with injectable form of naproxen

Potent, selective beta3-agonist from Merck & Co.

Demeter reports results with Peptidyl MIM in animal model of prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...